It is a Glucagon-like Peptide-1 (GLP-1) receptor agonist that mimics the GLP-1 hormone to increase insulin secretion
The right maintenance dose is the one that produces consistent results with tolerable side effects
Limitations Nasal sprays lower bioavailability results in 30%-50% less systemic exposure compared to injection, based on pharmacokinetic sampling in current trials
These are controlled, deliberate movements that focus on proper form, muscle engagement, and steady resistance
These results are roughly in line with what Lilly has demonstrated for tirzepatide (22.5% and 20.9% respectively at 72 weeks), but fall short of the 25% bar for efficacy many investors were anticipating, BMO Capital Markets analysts wrote in a note to investors
However, prescriptions should always be issued by a licensed healthcare provider who has evaluated your medical history